INVAのチャート
INVAの企業情報
| symbol | INVA |
|---|---|
| 会社名 | Innoviva Inc （テラバンス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | 医薬品 医療関連（Health Care） |
| 概要 | 事業概要 イノーバ（Innoviva Inc.）(旧名：Theravance Inc.)はバイオ医薬品の生産・商業化、及び財務管理に従事する。同社は、RELVAR / BREO ELLIPTA（フルチカゾンフロエート（FF）/ビランテロール（VI））及びANORO ELLIPTA（臭化ウムクリジニウム/ビランテロール（UMEC / VI））を含むGlaxo Group Limited (GSK) と提携した呼吸器資産に焦点を当てる。GSKとの長期契約ベータ2アゴニスト（LABA）コラボレーション契約および戦略的アライアンス契約に基づき、同社はリルバール/ブリオ・エルピタの販売においてGSKから年間ロイヤルティを受け取る資格がある。ANORO ELLIPTA等のLABAコラボレーションのLABAと組み合わされた他の製品については、ロイヤルティは上向きで6.5％から10％の範囲である。RELVAR / BREOは、LABA（VI）と吸入コルチコステロイド（ICS）、FFで構成される一日一回の組み合わせ吸入呼吸器薬である。ANORO ELLIPTAは、長時間作用型ムスカリンアンタゴニスト（LAMA）、臭化ウムクリジニウム（UMEC）、LABAを組み合わせた1日1回の薬である。 テラバンスは米国のバイオ医薬品メ―カ―。主に呼吸器疾患、細菌感染、中枢神経系疼痛などの治療分野における小分子薬の発見・開発・製品化に従事。主な製品候補は、「RELVAR」、「BREO」、「ELLIPTA」、「ANORO」、「MABA」。それぞれがグラクソ・スミスクラインとの長時間作用型ムスカリン拮抗薬プログラムと提携。 Innoviva, Inc. is a healthcare focused asset management company. The Company intends to participate in the development, commercialization and financial management of bio-pharmaceuticals. Innoviva operates in the United States. |
| 本社所在地 | 2000 Sierra Point Parkway Suite 500 Brisbane CA 94005 USA |
| 代表者氏名 | William H. Waltrip ウィリアムH.ウォルトリット |
| 代表者役職名 | Independent Chairman of the Board |
| 電話番号 | +1 650-238-9600 |
| 設立年月日 | 35370 |
| 市場名 | NASDAQ National Market System |
| ipoyear | ―年 |
| 従業員数 | 12人 |
| url | www.inva.com |
| nasdaq_url | https://www.nasdaq.com/symbol/inva |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） 223.72800 |
| 終値（lastsale） | 15.36 |
| 時価総額（marketcap） | 1559158963.2 |
| 時価総額 | 時価総額（百万ドル） 1591.641 |
| 売上高 | 売上高（百万ドル） 237.62900 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 1970.626 |
| 当期純利益 | 当期純利益（百万ドル） 166.35900 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Innoviva Inc revenues increased 21% to $119.5M. Net income increased 62% to $84.2M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net income benefited from Interest expense decrease of 43% to $14.1M (expense) General and administrative decrease of 41% to $9.8M (expense) Stock Based Comp. |
INVAのテクニカル分析
INVAのニュース
Innoviva Reports Fourth Quarter 2022 Financial Results and Highlights Recent Company Progress 2023/02/28 21:10:00 Business Wire
BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or “the Company”), a diversified holding company with a portfolio of royalties and other healthcare assets, today reported financial results for the fourth quarter ended December 31, 2022. Gross royalty revenues of $54.7 million from Glaxo Group Limited (“GSK”) for the fourth quarter of 2022 included royalties of $44.3 million from global net sales of RELVAR®/BREO® ELLIPTA® and royalties of $10.4 million from global
Four Undervalued Healthcare Stocks For 2023 2023/01/06 21:56:16 ValueWalk
Pfizer Inc. could outperform with consistent dividend and revenue growth. Regeneron Pharmaceuticals Inc. has a high P/E with a low upside but value could increase on continued revenue growth. Innoviva Inc. started the year heavily down but strong revenue gains could offset projected losses. Exelixis Inc. is near its 52-week bottom but a furtive P/E […]
Innoviva: Not Yet Investment Worthy (NASDAQ:INVA) 2022/12/15 18:51:15 Seeking Alpha
I think the most recent financial results of Innoviva are a mixed bag at best: revenue is down, profits are up. Click here to read my analysis of INVA stock.
Innoviva''s bacterial infection drug gets FDA priority review 2022/12/01 10:05:18 Seeking Alpha
The U.S. Food and Drug Administration ((FDA)) granted priority review to Innoviva''s (INVA) application seeking approval of SUL-DUR to treat infections caused by…
Innoviva GAAP EPS of $2.80, revenue of $67.26M 2022/11/09 22:52:05 Seeking Alpha
Innoviva press release (NASDAQ:INVA): Q3 GAAP EPS of $2.80.Revenue of $67.26M (-31.3% Y/Y).
Innoviva Stock? Not Yet. Short Puts? Definitely. (NASDAQ:INVA) 2022/09/19 19:40:28 Seeking Alpha
I think the problem of higher revenues and lower profits lingers, and I think there''s risk in the recent acquisitions. Read more about INVA here.
Innoviva to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference 2022/09/08 11:00:00 Business Wire
BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (Nasdaq: INVA) (“Innoviva”), a diversified holding company with a portfolio of royalties and a growing portfolio of innovative healthcare assets, today announced that Pavel Raifeld, Chief Executive Officer, will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on Wednesday, September 14th at 11:10 a.m. Eastern Time. A live webcast of the fireside chat can be accessed under “Events & Presentation
Innoviva Inc. (INVA) Worth Considering For The Next Few Weeks 2022/09/03 13:30:00 Stocks Register
Innoviva Inc. (NASDAQ:INVA) concluded the trading at $13.08 on Friday, September 02 with a rise of 0.54% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $13.01 and 5Y monthly beta was reading 0.50 with its price kept floating in the range … Innoviva Inc. (INVA) Worth Considering For The Next Few Weeks Read More »
Innoviva Completes Purchase of La Jolla Pharmaceutical 2022/08/22 13:10:01 Investing.com
https://www.investing.com/news/pro/innoviva-completes-purchase-of-la-jolla-pharmaceutical-432SI-2877480
Innoviva''s Return On Capital Employed Overview 2022/08/01 14:10:44 Benzinga
Pulled from Benzinga Pro data, Innoviva (NASDAQ: INVA ) showed a loss in earnings since Q1, totaling $21.37 million. Sales, on the other hand, increased by 20.17% to $108.22 million during Q2. Innoviva earned $37.86 million, and sales totaled $90.06 million in Q1. What Is Return On Capital Employed? Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company''s ROCE. A higher ROCE is generally representative of successful growth of a company and … Full story available on Benzinga.com
Innoviva''s Return On Capital Employed Overview 2022/08/01 14:10:44 Benzinga
Pulled from Benzinga Pro data, Innoviva (NASDAQ: INVA ) showed a loss in earnings since Q1, totaling $21.37 million. Sales, on the other hand, increased by 20.17% to $108.22 million during Q2. Innoviva earned $37.86 million, and sales totaled $90.06 million in Q1. What Is Return On Capital Employed? Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company''s ROCE. A higher ROCE is generally representative of successful growth of a company and … Full story available on Benzinga.com
Innoviva: Q2 Earnings Insights 2022/07/27 22:09:54 Benzinga
Innoviva (NASDAQ: INVA ) reported its Q2 earnings results on Wednesday, July 27, 2022 at 04:00 PM. Here''s what investors need to know about the announcement. Earnings Innoviva missed estimated earnings by 84.85%, reporting an EPS … Full story available on Benzinga.com
Innoviva GAAP EPS of $0.05, revenue of $108.22M 2022/07/27 21:36:35 Seeking Alpha
Innoviva press release (INVA): Q2 GAAP EPS of $0.05.Revenue of $108.22M (+7.4% Y/Y).Royalties increased by 7% to $111.7 million in the second quarter of 2022, compared to the same…
Innoviva Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress 2022/07/27 20:05:00 Business Wire
BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” and “the Company”), a diversified holding company with a portfolio of royalties and a growing portfolio of healthcare assets in infectious disease and other areas of high unmet need, today reported financial results for the second quarter ended June 30, 2022. Gross royalty revenues of $111.7 million from Glaxo Group Limited (“GSK”) for the second quarter of 2022 included royalties of $59.3 million from global net sal
Goldman Sachs starts Innoviva with neutral rating, says royalty portfolio fairly valued 2022/07/20 17:10:16 Seeking Alpha
Shares of Innoviva (INVA) fell as much as 2.4% to $14.37 in Wednesday trading after Goldman Sachs initiated the company with a neutral rating.Goldman Sachs analyst Chris Shibutani gave…